QUÉBEC CITY, QC – November 16, 2006 – Advitech Inc. (TSX-V: AVI), one of Canada’s
leading health sciences and technology companies, today announced that an agreement has
been reached with celebrated former Canadian Olympian Pierre Harvey to promote the benefits
of the Company’s award-winning Dermylex™ psoriasis remedy.
Mr. Harvey, who is amongst an estimated one million Canadians who suffer from psoriasis, is
best known as the first Canadian male athlete to compete in both the 1984 Summer Olympics
(cycling) and the 1984 Winter Olympics (cross-country skiing). In 1988, he was named a member
of the Order of Canada. Mr. Harvey has since been inducted into the Canadian Ski Hall of Fame
(1992), Canadian Cycling Hall of Fame (2006) and Canadian Olympic Association Hall of Fame
“Suffering from mild to moderate psoriasis for many years, I heard about Dermylex and decided
to try it to see for myself its effect on this disease,” said Mr. Harvey. “Very rapidly, my psoriasis
has improved after taking Dermylex, a natural health product clinically proven and scientifically
supported to relieve mild to moderate psoriasis symptoms. I agreed to promote the product
because of my personal confidence in the product and its proven effectiveness, in my case.
Dermylex simply works very well.”
“This relationship with Pierre will permit Advitech to speak to Canadians about Dermylex with
authority while educating them about psoriasis in plain-spoken terms,” explained Renaud
Beauchesne, President and Chief Executive Officer, Advitech Inc. “It’s an important step in our
plan to increase our distribution, sales and market share growth of Dermylex in Canada.”
Developed by Advitech and distributed by Jamieson Laboratories, Dermylex is a patented blend
of bioactive peptides from a natural source, with properties that have been rigorously
demonstrated through scientific studies. It acts as an immune system regulator in auto-immune
diseases such as psoriasis. During clinical trials, patients who responded to Dermylex generally
began to see an improvement within 56 days.
Dermylex is not a topical treatment, but a tablet taken orally. This makes treatment more
convenient. It is also a product of natural origin. Its effectiveness has been demonstrated using
the same rigorous parameters as is used for pharmaceuticals, but it features the safety profile of
natural health products.
Dermylex is available in drug stores and does not require a prescription. The dosage is one 400
mg (milligram) tablet taken twice daily before meals. Dermylex does not replace other treatments
recommended by a patient’s health specialist. Patients allergic to dairy products must not use this
Dermylex is available at selected pharmacies and drug stores in Quebec and in other provinces
at a manufacturer’s suggested list price of $59.95.
Advitech is a life science and technology Company with the mission of discovering and
commercializing scientifically supported, patented natural health products. Effective and safe,
these products are designed to help counter Immune-Mediated Inflammatory Disorders (IMID),
such as psoriasis and inflammatory bowel diseases. Advitech’s common shares are listed on the
TSX Venture Exchange under the symbol AVI. The number of common shares outstanding is
54 799 818. The NEW Dermylex™ website is now online at www.dermylex.ca.
About Jamieson Laboratories
Established in 1922, Jamieson Laboratories is Canada's largest manufacturer and distributor of
advanced natural health care products. Jamieson's state-of-the-art pharmaceutical manufacturing
laboratories are located in Windsor, Ontario. The company is a world leader in the vitamin and
nutrition industry, exporting to over 45 countries including the USA, China, Japan, Hong Kong,
Korea and Singapore. For more information, please visit the Jamieson Laboratories website at
www.jamiesonvitamins.com or call 1 800 265-5088.
This press release contains forward-looking statements which reflect the Company's current
expectations regarding future events. The forward-looking statements involve risks and
uncertainties. Actual results could differ materially from those projected herein.
The TSX Venture Exchange does not accept responsibility for th
e adequacy or accuracy of this
For further information, please contact:
Renaud Beauchesne, MBA
President and Chief Executive Officer
(418) 686-7498, ext. 228